Hennion & Walsh Asset Management, Inc. Reata Pharmaceuticals Inc Transaction History

Hennion & Walsh Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$79.22 - $105.37 $1.02 Million - $1.36 Million	-12,888 Reduced 22.93%	43,316 $4.42 Million
Q1 2023 Apr 20, 2023	SELL	$30.85 - $93.17 $57,689 - $174,227	-1,870 Reduced 3.22%	56,204 $5.11 Million
Q4 2022 Jan 12, 2023	SELL	$22.15 - $42.11 $281,526 - $535,218	-12,710 Reduced 17.96%	58,074 $2.21 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $82,841 - $155,739	4,268 Added 6.42%	70,784 $1.78 Million
Q2 2022 Jul 19, 2022	BUY	$20.71 - $36.5 $379,676 - $669,154	18,333 Added 38.05%	66,516 $2.02 Million
Q1 2022 Apr 26, 2022	BUY	$24.12 - $39.6 $136,832 - $224,650	5,673 Added 13.35%	48,183 $1.58 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $69,787 - $302,366	2,725 Added 6.85%	42,510 $1.12 Million
Q3 2021 Nov 12, 2021	BUY	$100.0 - $143.02 $370,000 - $529,174	3,700 Added 10.25%	39,785 $4 Million
Q2 2021 Aug 13, 2021	BUY	$78.27 - $151.29 $29,351 - $56,733	375 Added 1.05%	36,085 $5.11 Million
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $3.37 Million - $4.74 Million	35,710 New	35,710 $3.56 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.